• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LAPTM5通过促进多发性骨髓瘤中的自噬体-溶酶体融合赋予对维奈托克的抗性。

LAPTM5 Confers the Resistance to Venetoclax via Promoting the Autophagosome-Lysosome Fusion in Multiple Myeloma.

作者信息

Li Yuxiang, Bai Jing, Liu Dan, Hao Jinxia, Yan Ruyu, Guo Hongjuan, Huang Yuzhi, Yu Hongtao, Leng Hao, Zhou Kecheng, Liu Minxia

机构信息

School of Life Sciences, Anhui Medical University, Hefei, China.

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.

出版信息

J Cell Mol Med. 2025 Jan;29(1):e70331. doi: 10.1111/jcmm.70331.

DOI:10.1111/jcmm.70331
PMID:39753521
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11702483/
Abstract

Multiple myeloma (MM) is a haematological lymphoid malignancy marked by significant morbidity due to severe complications. Despite advances in targeted therapies, including proteasome inhibitors and the BCL-2 inhibitor venetoclax, drug resistance frequently occurs, with the underlying mechanisms poorly understood. This study investigates the role of lysosome-associated protein transmembrane 5 (LAPTM5) in conferring resistance to venetoclax in relapsed MM. Using comprehensive analyses of publicly available databases and experimental validation, we demonstrated that LAPTM5 is upregulated and enhances autophagy in recurrent multiple myeloma cells, which is a key process for cell homeostasis and drug resistance. Mechanistic studies reveal that LAPTM5 facilitates autophagic flux, linking it to the cellular catabolic processes essential for survival under therapeutic stress. Our findings highlight the underexplored functions of LAPTM5 in modulating autophagy and drug resistance, we demonstrate that LAPTM5 confers resistance to venetoclax by enhancing autophagy, suggesting that targeting LAPTM5 may provide new avenues for overcoming treatment challenges. This research underscores the potential function of LAPTM5 as a therapeutic target in improving outcomes in MM treatment.

摘要

多发性骨髓瘤(MM)是一种血液系统淋巴恶性肿瘤,因严重并发症而具有较高的发病率。尽管包括蛋白酶体抑制剂和BCL-2抑制剂维奈克拉在内的靶向治疗取得了进展,但耐药性仍频繁出现,其潜在机制尚不清楚。本研究调查了溶酶体相关蛋白跨膜5(LAPTM5)在复发MM中赋予对维奈克拉耐药性的作用。通过对公开可用数据库的综合分析和实验验证,我们证明LAPTM5在复发性多发性骨髓瘤细胞中上调并增强自噬,这是细胞稳态和耐药性的关键过程。机制研究表明,LAPTM5促进自噬通量,将其与治疗应激下生存所必需的细胞分解代谢过程联系起来。我们的研究结果突出了LAPTM5在调节自噬和耐药性方面尚未充分探索的功能,我们证明LAPTM5通过增强自噬赋予对维奈克拉的耐药性,这表明靶向LAPTM5可能为克服治疗挑战提供新途径。这项研究强调了LAPTM5作为治疗靶点在改善MM治疗结果方面的潜在功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/314b41d0d5fc/JCMM-29-e70331-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/69e208db6d32/JCMM-29-e70331-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/0277a466a5f6/JCMM-29-e70331-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/0297610b54d0/JCMM-29-e70331-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/bad1c8e606c8/JCMM-29-e70331-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/ec1570c91fa6/JCMM-29-e70331-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/2620ade08843/JCMM-29-e70331-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/314b41d0d5fc/JCMM-29-e70331-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/69e208db6d32/JCMM-29-e70331-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/0277a466a5f6/JCMM-29-e70331-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/0297610b54d0/JCMM-29-e70331-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/bad1c8e606c8/JCMM-29-e70331-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/ec1570c91fa6/JCMM-29-e70331-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/2620ade08843/JCMM-29-e70331-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1969/11702483/314b41d0d5fc/JCMM-29-e70331-g003.jpg

相似文献

1
LAPTM5 Confers the Resistance to Venetoclax via Promoting the Autophagosome-Lysosome Fusion in Multiple Myeloma.LAPTM5通过促进多发性骨髓瘤中的自噬体-溶酶体融合赋予对维奈托克的抗性。
J Cell Mol Med. 2025 Jan;29(1):e70331. doi: 10.1111/jcmm.70331.
2
Targeting Bcl-2 for the treatment of multiple myeloma.针对 Bcl-2 治疗多发性骨髓瘤。
Leukemia. 2018 Sep;32(9):1899-1907. doi: 10.1038/s41375-018-0223-9. Epub 2018 Aug 3.
3
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.BCL-2、BCL-XL和MCL-1的表达谱预测多发性骨髓瘤模型对BCL-2选择性拮抗剂维奈托克的药理反应。
Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.
4
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention.探索多发性骨髓瘤中维奈托克耐药性的BCL2调控及上游信号转导:治疗干预的潜在途径
Blood Cancer J. 2025 Feb 5;15(1):10. doi: 10.1038/s41408-025-01215-x.
5
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.基质介导的多发性骨髓瘤中 miR-193b-3p 和 miR-21-5p 失调诱导的 MCL-1 和 BCL-2 表达变化导致 S63845 和 Venetoclax 耐药。
Cells. 2021 Mar 4;10(3):559. doi: 10.3390/cells10030559.
6
Venetoclax for the treatment of multiple myeloma.维奈托克治疗多发性骨髓瘤。
Expert Rev Hematol. 2018 Dec;11(12):915-920. doi: 10.1080/17474086.2018.1548931. Epub 2018 Dec 6.
7
Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.维奈托克、硼替佐米和S63845(一种MCL1抑制剂)用于治疗多发性骨髓瘤。
J Pharm Pharmacol. 2020 May;72(5):728-737. doi: 10.1111/jphp.13240. Epub 2020 Feb 17.
8
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.电子传递链活性是多发性骨髓瘤中 venetoclax 敏感性的预测因子和靶点。
Nat Commun. 2020 Mar 6;11(1):1228. doi: 10.1038/s41467-020-15051-z.
9
Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.用一例对维奈托克敏感的难治性疾病解释多发性骨髓瘤中t(11;14)的生物学意义
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e556-e559. doi: 10.1016/j.clml.2020.05.028. Epub 2020 Jun 14.
10
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.血红素通过MEK-ERK信号传导和嘌呤生物合成促进多发性骨髓瘤对维奈托克耐药。
Blood. 2025 Feb 13;145(7):732-747. doi: 10.1182/blood.2024025690.

引用本文的文献

1
MAMDC2-AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma.MAMDC2-AS1在复发难治性多发性骨髓瘤中诱导铜死亡
Cancer Rep (Hoboken). 2025 May;8(5):e70216. doi: 10.1002/cnr2.70216.

本文引用的文献

1
A roadmap towards improving outcomes in multiple myeloma.多发性骨髓瘤治疗结果改善的路线图。
Blood Cancer J. 2024 Aug 12;14(1):135. doi: 10.1038/s41408-024-01115-6.
2
The function and mechanism of LAPTM5 in diseases.LAPTM5 在疾病中的功能和作用机制。
Biomed Pharmacother. 2024 Sep;178:117237. doi: 10.1016/j.biopha.2024.117237. Epub 2024 Aug 2.
3
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.多发性骨髓瘤:2024 年关于诊断、风险分层和治疗的更新。
Am J Hematol. 2024 Sep;99(9):1802-1824. doi: 10.1002/ajh.27422. Epub 2024 Jun 28.
4
LAPTM4B counteracts ferroptosis via suppressing the ubiquitin-proteasome degradation of SLC7A11 in non-small cell lung cancer.LAPTM4B 通过抑制非小细胞肺癌中 SLC7A11 的泛素-蛋白酶体降解来拮抗铁死亡。
Cell Death Dis. 2024 Jun 20;15(6):436. doi: 10.1038/s41419-024-06836-x.
5
Targeted protein degradation: from mechanisms to clinic.靶向蛋白降解:从机制到临床。
Nat Rev Mol Cell Biol. 2024 Sep;25(9):740-757. doi: 10.1038/s41580-024-00729-9. Epub 2024 Apr 29.
6
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.复发多发性骨髓瘤中针对 BCMA 的嵌合抗原受体 T 细胞反应和耐药的单细胞多组学剖析。
Nat Cancer. 2024 Sep;5(9):1318-1333. doi: 10.1038/s43018-024-00763-8. Epub 2024 Apr 19.
7
CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.CRIP1 通过双重调节蛋白酶体和自噬参与多发性骨髓瘤的发病机制。
EBioMedicine. 2024 Feb;100:104961. doi: 10.1016/j.ebiom.2023.104961. Epub 2024 Jan 9.
8
Nutrient-regulated control of lysosome function by signaling lipid conversion.通过信号脂质转化实现营养物质对溶酶体功能的调控。
Cell. 2023 Nov 22;186(24):5328-5346.e26. doi: 10.1016/j.cell.2023.09.027. Epub 2023 Oct 25.
9
Autophagy: Regulator of cell death.自噬:细胞死亡的调控者。
Cell Death Dis. 2023 Oct 4;14(10):648. doi: 10.1038/s41419-023-06154-8.
10
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.BCL-2 家族蛋白的过度磷酸化是淋巴瘤对 venetoclax 产生功能性耐药的基础。
J Clin Invest. 2023 Nov 15;133(22):e170169. doi: 10.1172/JCI170169.